u-62840 and Fibrosis

u-62840 has been researched along with Fibrosis* in 1 studies

Reviews

1 review(s) available for u-62840 and Fibrosis

ArticleYear
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.
    Advances in therapy, 2022, Volume: 39, Issue:9

    Interstitial lung diseases (ILD) encompasses a heterogeneous group of parenchymal lung diseases characterized by variable amounts of inflammation and fibrosis. The targeting of fibroblasts and myofibroblasts with antifibrotic treatments is a potential therapeutic target for these potentially fatal diseases. Treprostinil is unique among the prostacyclin mimetics in that it has distinct actions at additional prostaglandin receptors. Preclinical and clinical evidence suggests that treprostinil has antifibrotic effects through the activation of the prostaglandin E receptor 2 (EP

    Topics: Epoprostenol; Fibrosis; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis

2022